YMAB - Y-mAbs Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
28.00
+0.79 (+2.90%)
As of 2:18PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close27.21
Open27.36
Bid27.86 x 800
Ask28.00 x 900
Day's Range27.05 - 28.07
52 Week Range15.17 - 31.00
Volume145,095
Avg. Volume166,585
Market Cap957.424M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.69
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.00
Trade prices are not sourced from all markets
  • YmAbs Therapeutics, Inc. (YMAB) Q2 2019 Earnings Call Transcript
    Motley Fool

    YmAbs Therapeutics, Inc. (YMAB) Q2 2019 Earnings Call Transcript

    YMAB earnings call for the period ending June 30, 2019.

  • GlobeNewswire

    Y-mAbs Announces Second Quarter 2019 Financial Results and Recent Corporate Developments

    NEW YORK, Aug. 14, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • How Much Of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Do Insiders Own?
    Simply Wall St.

    How Much Of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Do Insiders Own?

    The big shareholder groups in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have power over the company. Institutions will...

  • GlobeNewswire

    Y-mAbs to Announce Second Quarter 2019 Financial and Operating Results on August 14

    NEW YORK, Aug. 07, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its second quarter 2019 financial and.

  • GlobeNewswire

    Y-mAbs Announces Successful Pre-BLA Meeting with FDA for Naxitamab

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has completed a successful Type B Pre-Biologics License Application (“Pre-BLA”) meeting with the U.S. Food and Drug Administration (“FDA”) regarding a potential pathway for FDA approval of naxitamab for the treatment of patients with relapsed/refractory high-risk neuroblastoma. At the meeting, the Company reached alignment with the FDA on an Accelerated Approval Pathway for naxitamab along with a rolling BLA submission.

  • GlobeNewswire

    Y-mAbs Announces Recruitment Status for Pivotal Trials

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the status of patient recruitment for the Company’s two pivotal phase II trials, one for omburtamab for the treatment of CNS/LM from neuroblastoma and the other for naxitamab for the treatment of relapsed/refractory high-risk neuroblastoma. The Company expects the study to remain open and continue enrolling patients until the product potentially becomes available on the market and believes it remains on target to file a biologic license application (“BLA”) by the end of 2019 under the breakthrough therapy designation (“BTD”) the Company previously received from the FDA.

  • GlobeNewswire

    Y-mAbs Secures Commercial Radiolabeling Capacity

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Company has entered a development, manufacturing and supply agreement with SpectronRx in South Bend, Indiana, to secure access to clinical and commercial scale radiolabeling capacity for omburtamab. The Company expects to file a biologics license application (“BLA”) for omburtamab for the treatment of CNS/LM from neuroblastoma during 2019. The facility will also serve as back-up for the Company’s overseas activities,” stated Thomas Gad, Founder, Chairman, President and Head of Business Development and Strategy.

  • GlobeNewswire

    Y-mAbs Announces Data to be Presented at 2019 SIOP

    NEW YORK, June 26, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • GlobeNewswire

    Y-mAbs Announces Data to be Presented at 2019 ASCO Annual Meeting

    NEW YORK, May 15, 2019 -- Y-mAbs Therapeutics, Inc., (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • GlobeNewswire

    Y-mAbs Announces Development Update on Cancer Vaccine Program

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, is pleased to announce a development update on its cancer vaccine program, the GD2-GD3 Vaccine. A total of 84 pediatric patients received the GD2-GD3 Vaccine, all of whom had prior relapses and finally regained second or later remissions before vaccine treatment.

  • GlobeNewswire

    Y-mAbs Announces First Quarter 2019 Financial Results and Recent Corporate Developments

    NEW YORK, May 10, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • GlobeNewswire

    Y-mAbs Therapeutics To Present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas

    NEW YORK, May 08, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • Here’s What Hedge Funds Think About Y-mAbs Therapeutics, Inc. (YMAB)
    Insider Monkey

    Here’s What Hedge Funds Think About Y-mAbs Therapeutics, Inc. (YMAB)

    At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]

  • GlobeNewswire

    Y-mAbs Therapeutics To Present At The H.C. Wainwright Global Life Sciences Conference in London

    NEW YORK, April 03, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • Have Insiders Been Buying Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares?
    Simply Wall St.

    Have Insiders Been Buying Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunatel...

  • GlobeNewswire

    Y-mAbs Announces 2018 Financial Results and Corporate Development Highlights

    NEW YORK, March 22, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • GlobeNewswire

    Y-mAbs Therapeutics To Present At Cowen’s 39th Annual Health Care Conference

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced today that Dr. Claus Møller, MD, Ph.D., Chief Executive Officer of Y-mAbs Therapeutics will provide an overview and update on the company's business at Cowen’s 39th Annual Health Care Conference in Boston, Massachusetts. The presentation will take place on Tuesday, March 12, 2019, at 8:40 AM Eastern Daylight Time, and the presentation deck will be made available on the Company website at the time of presentation. Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.

  • GlobeNewswire

    Y-mAbs Therapeutics to Present at PEGS Boston

    NEW YORK, Feb. 13, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • What Kind Of Investor Owns Most Of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)?
    Simply Wall St.

    What Kind Of Investor Owns Most Of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)?

    A look at the shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual Read More...

  • GlobeNewswire

    Y-mAbs Therapeutics To Present At 37th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Dec. 13, 2018 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • GlobeNewswire

    Y-mAbs Announces Appointment of Gérard Ber to its Board of Directors and Planned Departure of Michael Buschle

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the appointment of the molecular nuclear medicine executive, Dr. Gérard Ber, PhD to its board of directors, and the planned departure of Dr. Michael Buschle, PhD. The departure of Dr. Buschle and the appointment of Dr. Ber is effective December 11, 2018.

  • GlobeNewswire

    Y-mAbs Therapeutics Announces FDA Clearance of IND for its Bispecific GD2 Antibody

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that the U.S. Food and Drug Administration (“FDA”) has cleared the Investigational New Drug (“IND”) application for a humanized bispecific GD2 antibody. It is anticipated that a Phase 1/2 clinical trial will soon be initiated to begin screening patients with relapsed/refractory neuroblastoma, high grade osteosarcoma and other GD2(+) solid tumors, where patients have relapsed or refractory disease that is resistant to standard therapy.

  • GlobeNewswire

    Y-mAbs Announces Third Quarter 2018 Financial Results and Recent Corporate Developments

    NEW YORK, Nov. 13, 2018 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • GlobeNewswire

    Bispecific GD2 Antibody In Vivo Data to be Presented at ASH

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Dr. Jeong A Park from the Department of Pediatrics of Memorial Sloan-Kettering Cancer Center (MSK) will present preclinical data from the Company’s bispecific GD2 antibody in a poster presentation at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA on December 3, 2018, at 9:00 PM Eastern. Bispecific GD2 antibodies were tested in solid tumors in preclinical models with T-cells and were shown to exert anti-tumor effect against GD2(+) tumor xenografts or PDX tumors.